LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 5 of total 5

Search options

  1. Article ; Online: The pathogenesis of coronavirus-19 disease

    Alain C. Borczuk / Rhonda K. Yantiss

    Journal of Biomedical Science, Vol 29, Iss 1, Pp 1-

    2022  Volume 15

    Abstract: Abstract Severe acute respiratory syndrome-associated coronavirus-2 (SARS-CoV-2) is the causal agent of coronavirus disease-2019 (COVID-19), a systemic illness characterized by variably severe pulmonary symptoms, cardiac conduction abnormalities, ... ...

    Abstract Abstract Severe acute respiratory syndrome-associated coronavirus-2 (SARS-CoV-2) is the causal agent of coronavirus disease-2019 (COVID-19), a systemic illness characterized by variably severe pulmonary symptoms, cardiac conduction abnormalities, diarrhea, and gastrointestinal bleeding, as well as neurologic deficits, renal insufficiency, myalgias, endocrine abnormalities, and other perturbations that reflect widespread microvascular injury and a pro-inflammatory state. The mechanisms underlying the various manifestations of viral infection are incompletely understood but most data suggest that severe COVID-19 results from virus-driven perturbations in the immune system and resultant tissue injury. Aberrant interferon-related responses lead to alterations in cytokine elaboration that deplete resident immune cells while simultaneously recruiting hyperactive macrophages and functionally altered neutrophils, thereby tipping the balance from adaptive immunity to innate immunity. Disproportionate activation of these macrophages and neutrophils further depletes normal activity of B-cells, T-cells, and natural killer (NK) cells. In addition, this pro-inflammatory state stimulates uncontrolled complement activation and development of neutrophil extracellular traps (NETS), both of which promote the coagulation cascade and induce a state of “thrombo-inflammation”. These perturbations have similar manifestations in multiple organ systems, which frequently show pathologic findings related to microvascular injury and thrombosis of large and small vessels. However, the pulmonary findings in patients with severe COVID-19 are generally more pronounced than those of other organs. Not only do they feature inflammatory thromboses and endothelial injury, but much of the parenchymal damage stems from failed maturation of alveolar pneumocytes, interactions between type 2 pneumocytes and non-resident macrophages, and a greater degree of NET formation. The purpose of this review is to discuss the pathogenesis underlying organ damage ...
    Keywords COVID-19 ; SARS-CoV-2 ; Pathology ; Histology ; Mechanisms ; Medicine ; R
    Subject code 610
    Language English
    Publishing date 2022-10-01T00:00:00Z
    Publisher BMC
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  2. Article ; Online: Author Correction

    Nasser K. Altorki / Zachary H. Walsh / Johannes C. Melms / Jeffery L. Port / Benjamin E. Lee / Abu Nasar / Cathy Spinelli / Lindsay Caprio / Meri Rogava / Patricia Ho / Paul J. Christos / Ashish Saxena / Olivier Elemento / Bhavneet Bhinder / Casey Ager / Amit Dipak Amin / Nicholas J. Sanfilippo / Vivek Mittal / Alain C. Borczuk /
    Silvia C. Formenti / Benjamin Izar / Timothy E. McGraw

    Nature Communications, Vol 15, Iss 1, Pp 1-

    Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I–III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial

    2024  Volume 1

    Keywords Science ; Q
    Language English
    Publishing date 2024-01-01T00:00:00Z
    Publisher Nature Portfolio
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  3. Article ; Online: Global evolution of the tumor microenvironment associated with progression from preinvasive invasive to invasive human lung adenocarcinoma

    Nasser K. Altorki / Alain C. Borczuk / Sebron Harrison / Lauren K. Groner / Bhavneet Bhinder / Vivek Mittal / Olivier Elemento / Timothy E. McGraw

    Cell Reports, Vol 39, Iss 1, Pp 110639- (2022)

    2022  

    Abstract: Summary: To investigate changes in the tumor microenvironment (TME) during lung cancer progression, we interrogate tumors from two chest computed tomography (CT)-defined groups. Pure non-solid (pNS) CT density nodules contain preinvasive/minimally ... ...

    Abstract Summary: To investigate changes in the tumor microenvironment (TME) during lung cancer progression, we interrogate tumors from two chest computed tomography (CT)-defined groups. Pure non-solid (pNS) CT density nodules contain preinvasive/minimally invasive cancers, and solid density nodules contain invasive cancers. Profiling data reveal a dynamic interaction between the tumor and its TME throughout progression. Alterations in genes regulating the extracellular matrix and genes regulating fibroblasts are central at the preinvasive state. T cell-mediated immune suppression is initiated in preinvasive nodules and sustained with rising intensity through progression to invasive tumors. Reduced T cell infiltration of the cancer cell nests is more frequently associated with preinvasive cancers, possibly until tumor evolution leads to a durable, viable invasive phenotype accompanied by more varied and robust immune suppression. Upregulation of immune checkpoints occurs only in the invasive nodules. Throughout progression, an effector immune response is present but is effectively thwarted by the immune-suppressive elements.
    Keywords CP: Cancer ; Biology (General) ; QH301-705.5
    Subject code 610
    Language English
    Publishing date 2022-04-01T00:00:00Z
    Publisher Elsevier
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  4. Article ; Online: Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I–III non-small cell lung cancer

    Nasser K. Altorki / Zachary H. Walsh / Johannes C. Melms / Jeffery L. Port / Benjamin E. Lee / Abu Nasar / Cathy Spinelli / Lindsay Caprio / Meri Rogava / Patricia Ho / Paul J. Christos / Ashish Saxena / Olivier Elemento / Bhavneet Bhinder / Casey Ager / Amit Dipak Amin / Nicholas J. Sanfilippo / Vivek Mittal / Alain C. Borczuk /
    Silvia C. Formenti / Benjamin Izar / Timothy E. McGraw

    Nature Communications, Vol 14, Iss 1, Pp 1-

    survival outcomes and molecular correlates of a randomized phase II trial

    2023  Volume 14

    Abstract: Abstract We previously reported the results of a randomized phase II trial (NCT02904954) in patients with early-stage non-small cell lung cancer (NSCLC) who were treated with either two preoperative cycles of the anti-PD-L1 antibody durvalumab alone or ... ...

    Abstract Abstract We previously reported the results of a randomized phase II trial (NCT02904954) in patients with early-stage non-small cell lung cancer (NSCLC) who were treated with either two preoperative cycles of the anti-PD-L1 antibody durvalumab alone or combined with immunomodulatory doses of stereotactic radiation (DRT). The trial met its primary endpoint of major pathological response, which was significantly higher following DRT with no new safety signals. Here, we report on the prespecified secondary endpoint of disease-free survival (DFS) regardless of treatment assignment and the prespecified exploratory analysis of DFS in each arm of the trial. DFS at 2 and 3 years across patients in both arms of the trial were 73% (95% CI: 62.1–84.5) and 65% (95% CI: 52.5–76.9) respectively. For the exploratory endpoint of DFS in each arm of the trial, three-year DFS was 63% (95% CI: 46.0–80.4) in the durvalumab monotherapy arm compared to 67% (95% CI: 49.6–83.4) in the dual therapy arm. In addition, we report post hoc exploratory analysis of progression-free survival as well as molecular correlates of response and recurrence through high-plex immunophenotyping of sequentially collected peripheral blood and gene expression profiles from resected tumors in both treatment arms. Together, our results contribute to the evolving landscape of neoadjuvant treatment regimens for NSCLC and identify easily measurable potential biomarkers of response and recurrence.
    Keywords Science ; Q
    Subject code 610
    Language English
    Publishing date 2023-12-01T00:00:00Z
    Publisher Nature Portfolio
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  5. Article ; Online: Integrative network analysis of early-stage lung adenocarcinoma identifies aurora kinase inhibition as interceptor of invasion and progression

    Seungyeul Yoo / Abhilasha Sinha / Dawei Yang / Nasser K. Altorki / Radhika Tandon / Wenhui Wang / Deebly Chavez / Eunjee Lee / Ayushi S. Patel / Takashi Sato / Ranran Kong / Bisen Ding / Eric E. Schadt / Hideo Watanabe / Pierre P. Massion / Alain C. Borczuk / Jun Zhu / Charles A. Powell

    Nature Communications, Vol 13, Iss 1, Pp 1-

    2022  Volume 17

    Abstract: The molecular factors that drive invasiveness and metastasis in lung adenocarcinoma (LUAD) are not completely understood. Here, the authors use an integrative network approach to identify a gene signature of invasiveness in LUAD, and reveal Aurora ... ...

    Abstract The molecular factors that drive invasiveness and metastasis in lung adenocarcinoma (LUAD) are not completely understood. Here, the authors use an integrative network approach to identify a gene signature of invasiveness in LUAD, and reveal Aurora kinases as master regulators of invasion.
    Keywords Science ; Q
    Language English
    Publishing date 2022-03-01T00:00:00Z
    Publisher Nature Portfolio
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

To top